跳至主要内容
临床试验/NCT01078714
NCT01078714已完成3 期

Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children

University Hospital, Brest3 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2010年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
60
试验地点
3
主要终点
Child Autism Rating Scale score

研究概览

简要总结

The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
3 Years 至 10 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the WHO ( CIM-10) and the parents of which gave a free, enlightened and written consent.

排除标准

  • Patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system
  • Patients autistics receiving a psychotropic treatment
  • Patients presenting disorders electrolytes
  • Patients presenting a hypersensibility known about sulpha drugs
  • Presenting patients against indications relative to the treatment by bumetanide
  • Patients already treated by diuretics
  • Patients presenting a hepatic or renal incapacity
  • Patients presenting an elongation of the QT to the electrocardiogram.
  • Patients autistics of CARS sore is lower than 30.

研究组 & 干预措施

Bumetanide

Experimental

干预措施: bumetanide (Drug)

Control

Placebo Comparator

干预措施: bumetanide (Drug)

结局指标

主要结局

Child Autism Rating Scale score

时间窗: day 0 to day 90

次要结局

  • Clinical global impressions score(day 0 to day 90)
  • Repetitive end restricted behavior score(day 0 to day 90)
  • GRAM score(day 0 to day 90)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验